银屑病关节炎、银屑病与健康对照的合并症、疼痛与疲劳:临床队列研究
本研究纳入初始使用传统合成或生物改善病情抗风湿药的PsA患者,基线及4个月后采集合并症与临床/患者报告结局,并与无关节炎的皮肤银屑病患者及健康对照比较。结果显示肥胖、高血压及CCI≥1与较差的治疗结局相关;PsA患者基线疼痛、疲劳及广泛疼痛均高于银屑病和健康对照。
要点
- 肥胖患者达到DAPSA50的比例显著低于无肥胖者(P=0.035)。
- 高血压(P=0.034)及CCI≥1(P=0.027)患者达到MDA的比例显著更低。
- PsA基线疼痛、疲劳(均P<0.001)及广泛疼痛(P=0.002)高于银屑病和健康对照。
核心结论
- 肥胖、高血压和CCI≥1是PsA治疗结局率较差的预后因素。
- PsA患者较皮肤银屑病和健康对照更常报告疼痛和疲劳。
研究设计与样本
- 临床观察性队列研究,基线纳入100例初始使用传统合成或生物改善病情抗风湿药的PsA患者,基线及4个月后采集数据。
- 采用Pearson卡方检验分析预设合并症与ACR20、DAPSA50、MDA达标的关系,用Mann-Whitney U检验比较OMERACT PsA核心结局集指标。
- 基线数据与无关节炎的皮肤银屑病患者及健康对照比较。
主要发现
- 肥胖患者达到DAPSA50的比例显著低于无肥胖者(P=0.035)。
- 高血压患者(P=0.034)及CCI≥1患者(P=0.027)达到MDA的比例分别显著低于无相应合并症者。
- 肥胖、高血压、广泛疼痛及CCI≥1患者在随访时OMERACT PsA核心结局集指标显著更差。
- 基线时PsA患者疼痛(P<0.001)和疲劳(P<0.001)评分更高,广泛疼痛更多(P=0.002)。
关键数值与推荐
- DAPSA50达标率在肥胖与无肥胖患者间差异有统计学意义(P=0.035)。
- MDA达标率在高血压与无高血压患者间(P=0.034)、CCI≥1与CCI<1患者间(P=0.027)差异有统计学意义。
- 基线疼痛和疲劳评分PsA高于皮肤银屑病和健康对照(均P<0.001),广泛疼痛差异P=0.002。
临床怎么用
- 对PsA患者应评估肥胖、高血压及CCI等合并症,以识别治疗结局可能较差者。
- PsA患者疼痛和疲劳负担重,临床评估中应关注患者报告结局。
局限性
- 基线仅纳入100例PsA患者,样本量有限。
- 随访时间为4个月,未能反映长期治疗结局。
- 研究为观察性设计,合并症与结局的关系不能推断因果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To explore the prognostic value of pre-specified comorbidities on treatment outcomes in PsA, and to compare baseline data with cutaneous psoriasis without arthritis and healthy controls (HC). METHODS: Patients initiating conventional synthetic/biological disease-modifying antirheumatic drugs were enrolled in this clinical observational cohort study, and data on comorbidities, and clinical and patient-reported outcomes were retrieved at baseline and after 4 months. Pearson's chi-squared tests were performed to investigate the prognostic value of pre-specified comorbidities and achievement of ACR20, DAPSA50 and MDA. Mann-Whitney U tests were used to compare OMERACT PsA Core Outcome Set (COS) measures at baseline and follow-up for the pre-specified comorbidities. RESULTS: A total of 100 PsA patients were included at baseline. Statistically significantly fewer patients with obesity achieved DAPSA50 compared with patients without obesity (P =0.035), and fewer patients with hypertension (P =0.034) and Charlson Comorbidity Index (CCI) ≥1 (P =0.027), respectively, achieved MDA compared with patients without these comorbidities. Patients with obesity, hypertension, widespread pain, and CCI ≥1 had significantly worse COS measures at follow-up compared with patients without these comorbidities. At baseline, patients with PsA had higher disease burden compared with patients with cutaneous psoriasis and HC, including higher pain (P <0.001) and fatigue (P <0.001) scores, and more widespread pain (P =0.002). CONCLUSION: Obesity, hypertension and CCI ≥1 were prognostic factors for poorer treatment outcome rates in PsA. Pain and fatigue were more frequently reported among patients with PsA compared with patients with cutaneous psoriasis and HC. TRIAL REGISTRATION: The Danish National Committee on Health Research Ethics: H-15009080; Data Protection Agency: 2012-58-0004; ClinicalTrials.gov: NCT02572700.
引用
- Ballegaard C, Skougaard M, Guldberg-Møller J, et al. Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study. Rheumatology (Oxford). 2021. PMID: 33325531. doi:10.1093/rheumatology/keaa780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。